January 29, 2024 09:44 PM EST
People
Cell/Gene Tx

CAR NK biotech Cata­ma­ran Bio to wind down, will seek part­ners for cell ther­a­pies

Kyle LaHucik

Senior Reporter

Off-the-shelf cell ther­a­py biotech Cata­ma­ran Bio made a “re­cent de­ci­sion to com­mence wind-down,” CEO Alvin Shih told End­points News in an email on Mon­day. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times